We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

69 hedge funds and large institutions have $2.25B invested in Verve Therapeutics in 2021 Q2 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

81.71% more ownership

Funds ownership: 0% → 81.71% (+82%)

Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AI
Alphabet Inc
California
+$456M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$165M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$143M
4
CC
Casdin Capital
New York
+$126M
5
RG
Redmile Group
California
+$80.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$661M +$456M +10,974,011 New
Wellington Management Group
2
Wellington Management Group
Massachusetts
$232M +$165M +3,965,479 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$208M +$143M +3,449,794 New
CC
4
Casdin Capital
New York
$183M +$126M +3,038,167 New
RG
5
Redmile Group
California
$117M +$80.4M +1,936,530 New
BBA
6
Baker Bros. Advisors
New York
$85.3M +$58.8M +1,416,530 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$79.8M +$58.7M +1,413,771 New
RSCM
8
Rock Springs Capital Management
Maryland
$58M +$40M +962,826 New
JP Morgan Chase
9
JP Morgan Chase
New York
$55.4M +$38.2M +920,252 New
RCM
10
RA Capital Management
Massachusetts
$53M +$36.5M +880,284 New
Citadel Advisors
11
Citadel Advisors
Florida
$48.7M +$34.4M +829,589 New
NHAS
12
Novo Holdings A/S
Denmark
$47.8M +$32.9M +793,265 New
LGM
13
Logos Global Management
California
$45.7M +$31.5M +758,265 New
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$41.3M +$28.4M +685,000 New
CAM
15
Cormorant Asset Management
Massachusetts
$40.6M +$29.4M +709,224 New
AIM
16
ARK Investment Management
Florida
$33M +$22.8M +548,389 New
BlackRock
17
BlackRock
New York
$31.9M +$22M +529,924 New
AG
18
Artal Group
Luxembourg
$30.1M +$20.8M +500,000 New
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$27.2M +$18.7M +451,680 New
Millennium Management
20
Millennium Management
New York
$24.7M +$17M +409,994 New
Federated Hermes
21
Federated Hermes
Pennsylvania
$22.3M +$15.4M +370,000 New
Jennison Associates
22
Jennison Associates
New York
$22.3M +$15.4M +370,000 New
WP
23
Woodline Partners
California
$12.5M +$8.59M +206,921 New
Goldman Sachs
24
Goldman Sachs
New York
$7.14M +$4.92M +118,513 New
DGM
25
Darwin Global Management
Jersey
$6.21M +$4.28M +103,013 New
1
2 3

VERV Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2021, worth a combined $2.25B.

Buyers outnumbered sellers: 69 funds opened new VERV positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Alphabet Inc, opening a new position worth an estimated $456M.

  • 69 institutional investors held Verve Therapeutics (VERV) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $2.25B of Verve Therapeutics stock for Q2 2021.
  • 69 funds opened new Verve Therapeutics positions in Q2 2021 and 0 closed out, a net change of +69 holders.
  • The largest Verve Therapeutics buyer in Q2 2021 was Alphabet Inc, an estimated $456M added.

Based on aggregated 13F filings for Q2 2021.